LOGIN  |  REGISTER
Viking Therapeutics

Latest Diagnostics & Research News

Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting

Studies include nearly 25,000 patients across multiple indications, showcasing the clinical impact of Signatera Breast: 8 accepted abstracts (4 oral presentations), including interim analysis from the randomized Signatera-guided interventional DARE trial; a large real-world study of metastatic treatment monitoring; and two readouts from the ISPY-2 trial Signatera Genome: Large-scale, pan-cancer performance of Signatera Genome assay GI,...Read more


Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025

May 22
Last Trade: 56.48 -0.41 -0.72

MADISON, Wis. / May 22, 2025 / Business Wire / Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30–June 3, 2025, in Chicago, Ill. Presentations include new data on the Oncodetect™ molecular residual disease (MRD) test, multi-cancer early detection (MCED)...Read more


Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting

May 22
Last Trade: 37.05 -0.04 -0.11

Plenary session to highlight use of Guardant360 CDx test in detecting emerging ESR1 mutations during first line endocrine therapy in advanced breast cancer in Phase 3 SERENA-6 trial Oral session to feature largest study evaluating tissue-free epigenomic-based molecular residual disease (MRD) detection in colon cancer using Guardant Reveal PALO ALTO, Calif. / May 22, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading...Read more


Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting

New data from the INSIGHT study demonstrates the VeriStrat Host Immune Classifier (HIC)’s ability to predict overall survival in patients with non-small cell lung cancer treated with immunotherapy LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual...Read more


QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions

May 22
Last Trade: 42.32 0.00 0.00

Partnership designed to expand QIAGEN’s leadership in oncology-focused digital PCR assays, advancing QIAcuity as the platform of choice for cancer research Combines QIAGEN’s global reach and automation expertise with ID Solutions’ assay development for research purposes and manufacturing strengths VENLO, Netherlands / May 22, 2025 / Business Wire / QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new commercial...Read more


Inotiv to Present at Jefferies Global Healthcare Conference 2025

WEST LAFAYETTE, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer will present at the upcoming Jefferies Global Healthcare Conference in...Read more


PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene

May 22
Last Trade: 0.95 -0.03 -3.18

Haorui’s established footprint brings HiFi sequencing to new customers including hospital labs and regional blood centers MENLO PARK, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced the appointment of Haorui Gene, a globally recognized leader in blood typing genomics, as an official distributor in China. The distribution...Read more


Twist Bioscience and Element Biosciences Expand Collaboration to Transform Next Generation Sequencing Workflows with Co-Developed End-to-End Solutions

May 22
Last Trade: 28.16 -0.31 -1.09

Offer end-to-end workflow from library prep through sequencing Twist to be sole provider of new Trinity™ library prep and target enrichment kits for Element AVITI™ sequencer Joint commercial activities to expand customer access to new NGS tools SOUTH SAN FRANCISCO, Calif. & SAN DIEGO / May 22, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences...Read more


Tempus AI to Present at the William Blair 45th Annual Growth Stock Conference

CHICAGO / May 21, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the William Blair 45th Annual Growth Stock Conference. The event will take place from June 3-5 in Chicago, IL. Jim Rogers, Chief Financial Officer of Tempus, will present on June 5. A live audio webcast of the presentation will be available here. About...Read more


Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors

May 21
Last Trade: 37.05 -0.04 -0.11

Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test PALO ALTO, Calif. / May 21, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the addition of a full suite of immunohistochemistry (IHC) testing to the company’s portfolio of tumor molecular profiling tests. This new...Read more


Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio

May 21
Last Trade: 348.46 1.10 0.32

MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is...Read more


Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

May 21
Last Trade: 15.89 -0.13 -0.81

FRIENDSWOOD, Texas, May 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 7:35 a.m. Eastern time. A live audio webcast of the Company’s presentation will be available...Read more


BioMark Diagnostics Announces Breakthrough Publication Reinforcing Leadership in AI-Powered Metabolomics for Oncology

May 20
Last Trade: 0.27 0.00 0.00

Novel Graph Neural Network (N-GNN) Model Achieves Superior Accuracy in Early Lung Cancer Detection, Paving the Way for Enhanced Diagnostic Capabilities. Vancouver, British Columbia--(Newsfile Corp. - May 20, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leader in developing liquid biopsy tests for early cancer detection, today announced the publication of a significant study exploring an...Read more


Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer

May 20
Last Trade: 37.05 -0.04 -0.11

New Guardant Hereditary Cancer test offers germline testing to identify guideline-recommended genetic variants associated with cancer risk across 12+ tumor types Results help guide treatment decisions and enable healthcare providers to assess patient risk for secondary cancers PALO ALTO, Calif. / May 20, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the...Read more


VolitionRx Announces Successful Detection of Nucleosomes in Cats

May 19
Last Trade: 0.51 -0.0025 -0.49

Clinical Paper Published in BMC Veterinary Research HENDERSON, Nev., May 19, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the publication of "Evaluation of plasma nucleosome concentrations and the effect of pre-analytical variables in healthy cats" in BMC Veterinary Research. This is the first study to report the detection of nucleosomes in cats:...Read more


Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing

May 19
Last Trade: 90.48 0.65 0.72

The IDS i20 platform offers fully automated processing of specialty assays in endocrinology, allergy, autoimmune and infectious diseases, Alzheimer’s disease and therapeutic drug monitoring WALTHAM, Mass. / May 19, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS...Read more


Aspira Women's Health Announces First Quarter 2025 Financial Results and Provides Business Update

May 19
Last Trade: 0.08 0.00 0.00

AUSTIN, TX / ACCESS Newswire / May 19, 2025 / Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announced today its results of operations for the three-month period ended March 31, 2025. The Company also reported early progress under its new leadership team. Key financial...Read more


Izotropic's U.S. FDA Regulatory Pathway Greenlit, Company Provides Corporate Update

May 16
Last Trade: 0.32 -0.005 -1.54

Regulatory alignment with FDA confirmed, clearing path to pivotal U.S. clinical trial 150-page strategic business plan and advanced financial models completed Investor outreach launched to fund clinical execution and market entry Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - May 16, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company...Read more


IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials

May 16
Last Trade: 138.04 0.75 0.55

RESEARCH TRIANGLE PARK, N.C. / May 16, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has announced a strategic collaboration with the contract research organization arm of Sarah Cannon Research Institute, SCRI Development Innovations, aimed at transforming oncology trials for biopharma partners...Read more


Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

Company intends to provide an interim read out by the end of summer 2025 Top-line results anticipated in Q4 2025; study on track to support U.S. pivotal trial initiation in 2026 BERKELEY, Calif. and MAINZ, Germany, May 16, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it intends to...Read more


Spectral Medical to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

May 16
Last Trade: 0.83 -0.01 -1.19

TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, on Tuesday, May 20, 2025 at 11:30 a.m. ET at the Nasdaq headquarters in New York City, New...Read more


Quantum-Si Reports First Quarter 2025 Financial Results

May 15
Last Trade: 1.73 0.26 17.29

Launches and Delivers First Platinum® Pro Units Announces New Library Preparation Development Program BRANFORD, Conn. / May 15, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced financial results for the first quarter ended March 31, 2025. Press Release Highlights First quarter 2025 revenue of $842,000, an 84% increase over the...Read more


Aldevron and Integrated DNA Technologies Manufacture World’s First mRNA-based Personalized CRISPR Therapy

May 15
Last Trade: 187.48 0.67 0.36

N of 1 therapy uniquely developed, on demand, for infant with life-threatening rare metabolic disorder in six months Results published in The New England Journal of Medicine and showcased at American Society of Gene & Cell Therapy Annual Meeting FARGO, N.D. & CORALVILLE, Iowa / May 15, 2025 / Business Wire / Aldevron, a global leader in the production of DNA, RNA and protein, together with Integrated DNA Technologies (IDT), a...Read more


European Hematology Association Accepts Abstract from Telo Genomics for Presentation at The 2025 Congress

Toronto, Ontario--(Newsfile Corp. - May 15, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, today announced that the European Hematology Association ("EHA") has accepted Telo Genomics' abstract submission for a poster presentation during the upcoming EHA 2025 Congress. The new...Read more


Twist Bioscience to Present at William Blair 45th Annual Growth Stock Conference

May 15
Last Trade: 28.16 -0.31 -1.09

SOUTH SAN FRANCISCO, Calif. / May 15, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that Patrick Finn, Ph.D., president and COO of Twist Bioscience, will present at the William Blair 45th Annual Growth Stock Conference on Tuesday June 3, 2025 at 10:00 am Central Time in Chicago, Illinois. The...Read more


Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS

LOUISVILLE, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced that new data will be presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2025 Annual Meeting in Montreal, Quebec and at the American Thoracic Society (ATS) 2025 International Conference in San Francisco, California. The presentation titled “Time to Diagnosis of Lung...Read more


VolitionRx Announces First Quarter 2025 Financial Results and Business Update

May 15
Last Trade: 0.51 -0.0025 -0.49

Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., May 15, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the first quarter ended March 31, 2025.  Volition management will host a conference call tomorrow, May 16 at...Read more


Applied DNA Sciences Reports Second Quarter Fiscal 2025 Financial Results

May 15
Last Trade: 0.56 -0.02 -3.50

Therapeutic DNA Production Services Segment (LineaRx) Revenues Up 44% Y/Y, Contributing to a 6% Increase in Total Revenues  Intra-Quarter Investor Conference Call and Webcast Scheduled for June 3, 2025, at 4:30 PM ET  STONY BROOK, NY / ACCESS Newswire / May 15, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today reported financial results for...Read more


Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financial Results & Provides a Business Update

May 15
Last Trade: 0.74 -0.04 -4.66

DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2024 and the fiscal year then ended. Key Highlights and Developments Management continues to make significant progress on the execution of the profitability focused...Read more


bioAffinity Technologies Reports First Quarter 2025 Results

May 15
Last Trade: 0.28 -0.008 -2.83

CyPath® Lung sales up 276% year-over-year SAN ANTONIO / May 15, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for accurate, noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the three months ended March 31, 2025. Key Highlights Generated revenue of $1.9 million in the first quarter of...Read more


ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results

May 15
Last Trade: 3.13 0.04 1.29

ANN ARBOR, Mich. / May 15, 2025 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today provided a business update and reported financial results for the three months ended March 31, 2025. Business Update Incorporating Liver Diagnostics into the Management of Metabolic Disease ENDRA recently announced a strategic pivot to position the company to play an integral role in...Read more


Sera Prognostics To Present At RBC Global Healthcare Conference

SALT LAKE CITY , May 14, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the RBC Global Healthcare Conference on Wednesday, May 21, 2025, from 9:30 – 9:55 a.m. ET. Zhenya Lindgardt, President and CEO, will participate...Read more


Bionano Genomics Reports First Quarter 2025 Results and Highlights Recent Business Progress

May 14
Last Trade: 3.77 0.15 4.14

Conference call today, May 14, 2025, at 4:30 PM ET SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2025. “The first quarter of 2025 represents the first full quarter of execution after shifting strategy towards a focus on our base of routine users of optical genome mapping (OGM) and VIA™ software as the primary drivers of our...Read more


Tempus AI Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline

May 14
Last Trade: 59.36 1.22 2.10

CHICAGO / May 14, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new strategic collaboration to advance Boehringer Ingelheim’s growing cancer pipeline. The new, multi-year collaboration builds on foundational work the two companies have conducted in the last few years, leveraging data and AI to further advance therapeutic...Read more


MDxHealth Reports Q1-2025 Results

May 14
Last Trade: 2.06 -0.03 -1.44

Year-over-year Q1 revenues increase by 22% to $24.3 million 71% year-over-year improvement in adjusted EBITDA in first quarter Conference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31,...Read more


DarioHealth Reports First Quarter 2025 Financial and Operating Results

May 14
Last Trade: 0.72 0.03 4.04

First quarter revenue of $6.75 million, a 17% increase year-over-year, driven by employer and health plan (B2B2C) growth, and a decrease of 11% sequentially. Gross margin increased to 57.5% compared to 42.2% in the first quarter of 2024 Gross margin (non-GAAP) increased to 70.5%, up from 62.4% in the first quarter of 2024 Operating expenses decreased by 35% compared to the first quarter of 2024 and 16% sequentially, with additional...Read more


Precipio Announces its Q1-2025 Financial Results

May 14
Last Trade: 9.75 -0.15 -1.52

Conference call to follow tomorrow, May 15 at 5 PM EST NEW HAVEN, Conn., May 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), filed its 10-Q report today. The following are the highlights of the Company’s financial performance and outlook for 2025. “We remain confident in the Company’s trajectory, supported by strong year-over-year revenue growth, improved gross margins,...Read more


Tempus AI Announces Six Posters Accepted for Presentation at ISPOR 2025

CHICAGO / May 13, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation of six posters, including one oral presentation, at the 2025 annual meeting of the Professional Society for Health Economics and Outcomes Research (ISPOR), taking place May 13-16 in Montreal, Canada. Tempus researchers are showcasing scientific...Read more


IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day

WESTBROOK, Maine / May 13, 2025 / Business Wire / IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Andrew Emerson, Executive Vice President and Chief Financial Officer, and Tina Hunt, Executive Vice President, Global Strategy and Commercial, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 28, 2025 from 10:55 am – 11:25 am (EDT). A live...Read more


StageZero Life Sciences and ElevationMD Introduce Aristotle and AVRT for the Early Detection of Cancer

May 13
Last Trade: 0.04 0.00 0.00

TORONTO, ON  - TheNewswire - May 13, 2025 - StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), and ElevationMD (“ElevationMD”) today announced the introduction of Aristotle and AVRT for the early detection of cancer as well as screening for metabolic markers for identifying and managing the early warning signs of chronic disease for the prevention of cancer. StageZero is an integrated healthcare...Read more


Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications

May 13
Last Trade: 80.54 1.17 1.47

Building on reputation for unparalleled performance, latest software delivers even greater accuracy, with 30% improvement in structural variant calling New features include easy-to-use oncology apps, enhanced multiomics pipelines, and AWS F2 support enabling faster turnaround times SAN DIEGO, May 13, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of DRAGEN™ version 4.4 software (v4.4), the industry's...Read more


Neogen Announces Board Transition with Appointment of Andrea Wainer and Retirement of James P. Tobin

May 13
Last Trade: 6.19 -0.03 -0.48

LANSING, Mich. / May 13, 2025 / Business Wire / Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced today that James P. Tobin has chosen to retire from the Company’s Board of Directors, effective May 31, 2025. Mr. Tobin has served on Neogen’s Board since 2016 and currently chairs the Governance and Sustainability Committee and serves on the Audit Committee. James C. Borel, Chair of the Neogen Board...Read more


Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO

May 13
Last Trade: 84.83 -0.06 -0.07

SAN DIEGO / May 13, 2025 / Business Wire / DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose biosensing, today announced the promotion of Jake Leach to president, in addition to his current role as chief operating officer, which he has held since 2022. With more than 21 years of leadership experience at Dexcom, Mr. Leach helped steer the company’s biosensing platforms since the launch of its first commercial...Read more


HeartBeam Reports First Quarter 2025 Results

May 13
Last Trade: 1.59 0.005 0.32

Successfully Met Clinical Endpoints in the VALID-ECG Pivotal Study Showing 93.4% Overall Diagnostic Agreement for Assessment of Arrhythmia Productive Discussions with FDA on 510(k) Submission for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software Signed Strategic Collaboration with AccurKardia to Enhance Commercial Offering for Arrhythmia Assessment Added Two New US Patents to Robust IP Portfolio and Differentiated...Read more


Biodesix Announces First Quarter 2025 Results and Highlights

May 13
Last Trade: 0.36 -0.04 -9.90

Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025; Q1 2025 Net loss improved by 18% compared to Q1 2024; Updated 2025 Revenue Guidance to a range of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., May 13, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and...Read more


Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

May 12
Last Trade: 0.49 -0.006 -1.20

Announced capsid license agreement with Lilly to deliver genomic medicines for up to five central nervous system (CNS) disease targets. Received $18 million upfront license fee for first target and eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments, plus tiered royalties on potential net sales. Announced derisking milestones in pathway to anticipated biologics license application (BLA)...Read more


QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software

May 12
Last Trade: 42.32 0.00 0.00

Acquisition adds Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases Strengthens QIAGEN Digital Insights offering for small and mid-sized labs worldwide with easy-to-use, fast and flexible NGS data interpretation in a rapidly growing market Franklin complements QCI Interpret, QCI Precision Insights and QIAGEN’s leading genetic databases COSMIC and HGMD VENLO, the Netherlands & TEL...Read more


BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of Its Early-Stage Lung Cancer Test

May 12
Last Trade: 0.27 0.00 0.00

Study Published in a special issue of International Journal of Molecular Sciences Confirms Test's Ability to Distinguish Early Lung Cancer from Other Non-Cancerous Lung Diseases Vancouver, British Columbia--(Newsfile Corp. - May 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, today announced the publication of a pivotal study...Read more


Dr. Gloria Sheynkman from the University of Virginia to Present Pioneering Research utilizing Quantum-Si’s Next-Gen Protein Sequencing™ Platform in Upcoming Nature Webinar on May 15

BRANFORD, Conn. / May 12, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, is pleased to announce an upcoming Nature webinar featuring Gloria Sheynkman, Ph.D., Associate Professor, University of Virginia, who will present new findings from her recent preprint on sequencing proteoform variation with Next-Gen Protein Sequencing™ (NGPS™). The live webinar will...Read more


RadNet Reports First Quarter Financial Results and Revises Upwards 2025 Financial Guidance Ranges for Revenue and Adjusted EBITDA¹

May 11
Last Trade: 56.77 -1.29 -2.22

First quarter Revenue was negatively impacted by approximately $22 million and Adjusted EBITDA(1) was negatively impacted by approximately $15 million as a result of the Southern California wildfires and severe winter weather conditions Total Company Revenue increased 9.2% to $471.4 million in the first quarter of 2025 from $431.7 million in the first quarter of 2024 Revenue from the Digital Health reportable segment increased 31.1%...Read more


Exagen Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares

May 9
Last Trade: 6.03 0.26 4.51

CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its common stock at a public offering price of $5.25 per share on May 8, 2025, pursuant to the full exercise of the option granted by Exagen to the underwriter in connection with its previously announced public offering of...Read more


Spectral Medical Announces First Quarter and Provides Corporate Update

May 9
Last Trade: 0.83 -0.01 -1.19

Tigris Trial Enrollment completed Topline results expected to be released in August 2025 Entered into an up to US$10 million Promissory Note with Vantive to Fund Spectral to PMX commercialization TORONTO, May 09, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for...Read more


PacBio Announces First Quarter 2025 Financial Results

May 8
Last Trade: 0.95 -0.03 -3.18

MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results:   Q1 2025 Q1 2024 Revenue $37.2 million $38.8 million Instrument revenue $11.0 million $19.0 million Consumable revenue $20.1 million $16.0 million Service and other revenue $6.0 million $3.8 million Revio™...Read more


Illumina Reports Financial Results for First Quarter of Fiscal Year 2025

May 8
Last Trade: 80.54 1.17 1.47

Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis) GAAP operating margin of 15.8% and non-GAAP operating margin of 20.4% for Q1 2025 GAAP diluted EPS of $0.82 and non-GAAP diluted EPS of $0.97 for Q1 2025 Cash provided by operations of $240 million and free cash flow of $208 million for Q1 2025 For fiscal year 2025, we expect: Core Illumina revenue to decline between (1%)...Read more


Natera Reports First Quarter 2025 Financial Results

May 8
Last Trade: 152.48 1.39 0.92

AUSTIN, Texas / May 08, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025. Recent Strategic and Financial Highlights Generated total revenues of $501.8 million in the first quarter of 2025, compared to $367.7 million in the first quarter of 2024, an increase of 36.5%. Product revenues grew 37.1% over...Read more


Natera: Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress

Demonstrates Signatera’s ability to predict long-term outcomes in early-stage, high-risk breast cancers Several datasets will be presented, highlighting Natera’s leadership in breast cancer MRD AUSTIN, Texas / May 08, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, will present multiple datasets in breast cancer together with its collaborators at the 2025 ESMO Breast Cancer...Read more


Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer

May 8
Last Trade: 0.28 -0.008 -2.83

Dr. Gordon Downie shares case-based evidence demonstrating how CyPath® Lung improves diagnostic confidence and guides care in high-risk patients SAN ANTONIO / May 08, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer, today announced the release of a white paper authored by Dr. Gordon...Read more


Dario's Digital Health Solution Demonstrates Effectiveness in New Research Examining Flu Vaccination Awareness in High-Risk Populations

May 8
Last Trade: 0.72 0.03 4.04

New data, published in JMIR, demonstrates the value of personalized messaging encouraging flu vaccinations in Dario members with diabetes NEW YORK, May 8, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today new research published in the Journal of Medical Internet Research ("JMIR") demonstrating the effectiveness of personalized digital...Read more


Twist Bioscience and Ginkgo Bioworks Revise Collaboration

May 8
Last Trade: 28.16 -0.31 -1.09

New terms provide Twist with key license to long DNA technology and assets Ginkgo to continue ordering from Twist with no purchase minimums SOUTH SAN FRANCISCO, Calif. & BOSTON / May 08, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for...Read more


Co-Diagnostics Reports First Quarter 2025 Financial Results

May 8
Last Trade: 0.24 -0.01 -5.49

SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Results:   ● Revenue of $0.1 million, which declined from $0.5 million during the Q1 2024 primarily due to timing of grant...Read more


Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology

May 7
Last Trade: 3.93 -0.14 -3.44

SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) --  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision Oncology published a real-world study suggesting that the results of RiskScore® led clinicians to recommend breast cancer screening aligned with patients’ individual risk. RiskScore, Myriad’s clinically validated breast cancer risk assessment...Read more


Danaher to Present at Bank of America Securities Healthcare Conference

May 7
Last Trade: 187.48 0.67 0.36

WASHINGTON, May 7, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Thursday, May 15, 2025 at 10:00 a.m. PT. The event will be simultaneously webcast on www.danaher.com. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator,...Read more


QuidelOrtho Reports First Quarter 2025 Financial Results

May 7
Last Trade: 30.18 0.60 2.03

Total revenue of $693 million, growth of 5% as reported and 6% in constant currency, excluding COVID-19 and Donor Screening Strong execution on cost-savings initiatives driving improved margins and profitability Company maintains full-year 2025 financial guidance  First Quarter 2025 Results (all comparisons are to the prior year period) Total revenue was $693 million, as reported Non-respiratory revenue was $573 million,...Read more


Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update

Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million Year-to-date fiscal 2025 revenue declined 4.1% to $244.2 million Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and...Read more


Exagen Announces Proposed Public Offering of Common Stock

May 7
Last Trade: 6.03 0.26 4.51

CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering of shares of its common stock. In connection with the offering, Exagen intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares...Read more


bioAffinity Technologies Announces Closing of $3.25 Million Offering

May 7
Last Trade: 0.28 -0.008 -2.83

SAN ANTONIO / May 07, 2025 / Business Wire / bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has closed its previously announced best efforts offering of securities as described below for aggregate gross proceeds to the Company of $3.25 million, before deducting agent fees and other estimated expenses...Read more


VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced today that its world-leading NAMkind™ platform for liver toxicology prediction, provided as a commercial service to pharma companies, was featured in an oral presentation at the Digestive Disease Week Conference (San Diego, CA, May 2-6, 2025) showing best-in-class predictive power against a set of test liver compounds. VivoSim’s liver...Read more


Charles River Laboratories Announces First-Quarter 2025 Results

May 7
Last Trade: 135.60 0.62 0.46

First-Quarter Revenue of $984.2 Million First-Quarter GAAP Earnings per Share of $0.50 and Non-GAAP Earnings per Share of $2.34 Increases 2025 Guidance Repurchased $350 Million of Common Stock in First Quarter of 2025 WILMINGTON, Mass. / May 07, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2025. For the quarter, revenue was $984.2 million, a...Read more


Natera: Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows

May 7
Last Trade: 152.48 1.39 0.92

Study published in American Journal of Transplantation highlights strong sensitivity and specificity, along with a >37% reduction in false positives when using Prospera Heart with DQS Adds to the growing body of evidence supporting DQS for dd-cfDNA analysis in solid organ transplant AUSTIN, Texas / May 07, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced...Read more


Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update

May 7
Last Trade: 74.75 -0.38 -0.51

Worldwide revenue of $372.8 million in the first quarter 2025 GAAP fully diluted earnings per share of $1.02, compared to $1.87 in the first quarter of 2024; adjusted fully diluted earnings per share of $1.53, compared to $1.69 in the first quarter of 2024 Free cash flow totaled $98.8 million for the first quarter 2025 Closed acquisition of Evergreen Theragnostics early in the second quarter; expect to close on acquisition of Life...Read more


Spectral Medical Announces Non-Dilutive Financing of Up to $10 Million with Vantive

May 7
Last Trade: 0.83 -0.01 -1.19

Non-Dilutive Financing Up to US$10 Million Promissory Note Provided by Vantive If Fully Drawn, Promissory Note is Expected to Fully Fund Spectral to PMX Commercialization Company to host Corporate Update Call on May 15, 2025 TORONTO, May 07, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today...Read more


Sera Prognostics Reports First Quarter 2025 Financial Results

May 7
Last Trade: 1.88 -0.04 -2.08

SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights: Following release of full Prematurity Risk Assessment Combined With Clinical Interventions for...Read more


Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

May 6
Last Trade: 3.93 -0.14 -3.44

Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year. First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. MyRisk®testing volume in the affected population grew 11% year-over-year. First...Read more


Tempus AI Reports First Quarter 2025 Results

May 6
Last Trade: 59.36 1.22 2.10

CHICAGO / May 06, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin...Read more


Standard BioTools Reports First Quarter 2025 Financial Results

May 6
Last Trade: 0.95 -0.09 -8.27

SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: First quarter 2025 revenue of $40.8 million 45% reduction in operating loss and 29% improvement in adjusted EBITDA year-over-year Operationalized $10 million more in annual run rate cost...Read more


Thermo Fisher Scientific to Present at BofA Securities 2025 Health Care Conference on May 13

May 6
Last Trade: 400.48 2.20 0.55

WALTHAM, Mass. / May 06, 2025 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the BofA Securities Health Care Conference on Tuesday, May 13, 2025 at 11:40 a.m. (ET). The live webcast of the presentation can be accessed via the Investors section of our website, www.thermofisher.com. About Thermo...Read more


Neuronetics Reports First Quarter 2025 Financial and Operating Results

May 6
Last Trade: 3.99 -0.02 -0.50

MALVERN, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the first quarter of...Read more


IQVIA Reports First-Quarter 2025 Results

May 6
Last Trade: 138.04 0.75 0.55

Revenue of $3,829 million GAAP Net Income of $249 million, Adjusted EBITDA of $883 million GAAP Diluted Earnings per Share of $1.40, Adjusted Diluted Earnings per Share of $2.70 R&D Solutions quarterly bookings of $2.1 billion, resulting in trailing-twelve-month bookings of $9.7 billion and a trailing-twelve-month book-to-bill ratio of 1.14x R&D Solutions contracted backlog of $31.5 billion, up 4.8 percent year-over-year TAS...Read more


HeartBeam Announces Two New U.S. Patents, Powering Forward Its Robust Patent Portfolio

May 6
Last Trade: 1.59 0.005 0.32

First patent significantly advances intellectual property for HeartBeam’s credit card-sized ECG device, bolstering both the defensive and offensive moat around the company’s core technology Second patent expands the use of risk-based diagnostic algorithms into HeartBeam’s product portfolio around wearable devices HeartBeam now has 20 issued patents worldwide, cementing Company’s leadership in cardiac monitoring innovation SANTA...Read more


Waters Integrates Multi-Angle Light Scattering Detectors with Empower Software for Improved Biologics Quality Control and Simplified Regulatory Compliance

May 6
Last Trade: 348.46 1.10 0.32

News Summary  Saves up to six months on compliant software validation in biopharmaceutical quality control.1 Reduces analysis time for biotherapeutic peptides and proteins by 20%.2 Enhances quality control by providing absolute molecular weight of biologics and avoiding common errors encountered with other techniques.3 MILFORD, Mass., May 6, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that its Empower™...Read more


Waters Reports First Quarter 2025 Financial Results

May 6
Last Trade: 348.46 1.10 0.32

Highlights Strong start to the year as first quarter 2025 sales of $662 million landed at the high-end of guidance range; grew 4% as reported and 7% in constant currency Results led by instrument growth of 11% in constant currency, driven by strong momentum in Pharma and Industrial end markets Earnings landed at the high-end of guidance range with GAAP EPS of $2.03 and non-GAAP EPS of $2.25 Raising full-year constant currency sales...Read more


Castle Biosciences Reports First Quarter 2025 Results

May 5
Last Trade: 15.89 -0.13 -0.81

Q1 2025 revenue increased 21% over Q1 2024 to $88 million Q1 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, DecisionDx®-SCC, TissueCypher®) increased 33% over Q1 2024 Raising full-year 2025 revenue guidance to $287-297 million from $280-295 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company...Read more


Castle Biosciences to Acquire Previse

Expected to complement Castle’s current gastroenterology franchise Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in development FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire...Read more


First Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newborn Screening Launches in Thailand

May 5
Last Trade: 0.95 -0.03 -3.18

MENLO PARK, Calif. and BANGKOK, May 05, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB) a leading provider of high-quality, highly accurate sequencing platforms, and Chulalongkorn University, a national leader in genomic and translational research, today announced a strategic collaboration to implement PacBio HiFi whole genome sequencing (WGS) as part of a newborn screening research program. This marks the first initiative in Asia...Read more


Tempus AI Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry

CHICAGO / May 05, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of Notetaker, an AI-powered clinical assistant to aid psychiatrists in generating progress notes. Notetaker, which is available in Tempus Hub, ambiently records patient sessions to generate transcripts and clinical notes that can be seamlessly stored...Read more


Twist Bioscience Announces Fiscal 2025 Second Quarter Financial Results

May 5
Last Trade: 28.16 -0.31 -1.09

SOUTH SAN FRANCISCO, Calif. / May 05, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the second quarter fiscal 2025 ended March 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at...Read more


Natera: Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera

May 5
Last Trade: 152.48 1.39 0.92

Stanford-led study included over 2,100 Signatera samples from over 200 sarcoma patients, with overall sensitivity of 89% and specificity of 100% Leiomyosarcoma, the most common subtype in the cohort, demonstrated sensitivity of 93% and specificity of 100% AUSTIN, Texas / May 05, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the results of a study led by...Read more


BioNxt Solutions Reports Expanded Patent Protection from the Eurasian Patent Organization

May 5
Last Trade: 0.53 -0.01 -1.85

VANCOUVER, BC / ACCESS Newswire / May 5, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that its first national level patent filing has been accepted by the Eurasian Patent Organization (EAPO). The EAPO has confirmed the Company's core patent claims, namely: novelty, inventive step, and industrial...Read more


HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth

Board expansion reflects Company’s commitment to leadership and innovation in remote cardiac monitoring SANTA CLARA, Calif. / May 05, 2025 / Business Wire / HeartBeam, Inc., (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the appointment of Chief Executive Officer, Robert Eno, to its Board of Directors. As the Company continues to make...Read more


Exagen Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume

May 5
Last Trade: 6.03 0.26 4.51

CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025, and recent corporate updates.     Three Months Ended March 31,       2025       2024   (in thousands, except ASP...Read more


Sign Up To Get Daily
Life Science News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE